Compare NPWR & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPWR | EQ |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.0M | 157.4M |
| IPO Year | 2021 | 2018 |
| Metric | NPWR | EQ |
|---|---|---|
| Price | $1.70 | $2.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 743.5K | 477.7K |
| Earning Date | 05-11-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $0.76 |
| 52 Week High | $5.20 | $3.54 |
| Indicator | NPWR | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 47.48 |
| Support Level | $1.63 | $1.97 |
| Resistance Level | $1.84 | $2.61 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 40.16 | 59.32 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. Its business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. The company has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.